DUODOPA is indicated for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.1
This page is intended for UK healthcare professionals only with patients who have already been prescribed Duodopa (levodopa/carbidopa intestinal gel)
Patient Support Programme (PSP)
The PSP is a package deal developed and funded by AbbVie. Patients receiving Duodopa have access to a patient support service, provided free of charge to the NHS.
The service provides a team of Parkinson’s specialist nurses who deliver 1:1 care and support in hospitals and homes across the country.
This includes pre-assessment visits, support during NJ/PEG-J placement, 1:1 in-hospital titration guidance, follow-up home visits and ongoing support.
Duodopa nurses are available to support and educate the patient through every stage of the Duodopa treatment pathway.
Below is an introduction to the two AbbVie service partners who provide patient support as part of the PSP.
NJ=nasojejunal; PEG-J=percutaneous endoscopic gastro-jejunostomy.
This page is intended for UK healthcare professionals only with patients who have already been prescribed Duodopa
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on [email protected]
UK-DUOD-210222. Date of preparation: August 2022.
